Prospective Stratification of Infectious Risks in Multiple Sclerosis
NCT ID: NCT04036097
Last Updated: 2025-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
298 participants
OBSERVATIONAL
2019-04-10
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study
NCT03369106
Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50
NCT07313462
Immunodeficiency in MS
NCT04447937
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
NCT05941975
NARCOMS Registry: A Multiple Sclerosis Registry
NCT01018537
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MS-adapted AWIS questionnaire (MS-AWIS)
The predefined questionnaire-based infection score of the Airway Infection Susceptibility (AWIS) study is predictive for the occurrence of respiratory tract infections (RTI). In addition several MS-specific items (e.g. bladder dysfunction and urinary tract infections) are included into the AWIS questionnaire (MS-AWIS).
infection diary (MS-AWIS diary)
MS patients prospectively fill out monthly infection diaries for 24 months. Infection diaries will either be sent back (with pre-franked envelopes) or handed back to the InRIMS-study team during regular clinical visits (usually every 6 or 12 months).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* MS Patients with long-term antibiotic prophylaxis
* MS Patients with known primary immunodeficiency, under chemotherapy due to any malignancy or HIV infection.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swiss Multiple Sclerosis Society
UNKNOWN
Bangerter-Rhyner Stiftung
UNKNOWN
Center for Chronic Immunodeficiency (CCI) in Freiburg, Germany
UNKNOWN
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bernhard Décard, Dr. med
Role: PRINCIPAL_INVESTIGATOR
University Hospital Basel, Department of Neurology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Basel, Department of Neurology
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-00465; me18Decard
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.